Literature DB >> 27220659

International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r.

Ted M Burns1, Reza Sadjadi2, Kimiaki Utsugisawa3, Kelly G Gwathmey1, Amruta Joshi1, Sarah Jones1, Vera Bril4, Carolina Barnett4, Jeffrey T Guptill5, Donald B Sanders5, Lisa Hobson-Webb5, Vern C Juel5, Janice Massey5, Karissa L Gable5, Nicholas J Silvestri6, Gil Wolfe6, Gary Cutter7, Yuriko Nagane3, Hiroyuki Murai8, Masayuki Masuda9, Maria Elena Farrugia10, Caroline Carmichael10, Simone Birnbaum11, Jean-Yves Hogrel11, Shahriar Nafissi12, Farzad Fatehi12, Changyi Ou13, Weibin Liu13, Mark Conaway1.   

Abstract

INTRODUCTION: The MG-QOL15 is a validated, health-related quality of life (HRQOL) measure for myasthenia gravis (MG). Widespread use of the scale gave us the opportunity to further analyze its clinimetric properties.
METHODS: We first performed Rasch analysis on >1,300 15-item Myasthenia Gravis Quality of Life scale (MG-QOL15) completed surveys. Results were discussed during a conference call with specialists and biostatisticians. We decided to revise 3 items and prospectively evaluate the revised scale (MG-QOL15r) using either 3, 4, or 5 responses. Rasch analysis was then performed on >1,300 MG-QOL15r scales.
RESULTS: The MGQOL15r performed slightly better than the MG-QOL15. The 3-response option MG-QOL15r demonstrated better clinimetric properties than the 4- or 5-option scales. Relative distributions of item and person location estimates showed good coverage of disease severity.
CONCLUSIONS: The MG-QOL15r is now the preferred HRQOL instrument for MG because of improved clinimetrics and ease of use. This revision does not negate previous studies or interpretations of results using the MG-QOL15. Muscle Nerve 54: 1015-1022, 2016.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  MG-QOL15; MG-QOL15r; Rasch analysis; myasthenia; myasthenia gravis; quality of life; revised MG-QOL15

Mesh:

Year:  2016        PMID: 27220659     DOI: 10.1002/mus.25198

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  16 in total

1.  Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Authors:  James F Howard; Vera Bril; Ted M Burns; Renato Mantegazza; Malgorzata Bilinska; Andrzej Szczudlik; Said Beydoun; Francisco Javier Rodriguez De Rivera Garrido; Fredrik Piehl; Mariarosa Rottoli; Philip Van Damme; Tuan Vu; Amelia Evoli; Miriam Freimer; Tahseen Mozaffar; E Sally Ward; Torsten Dreier; Peter Ulrichts; Katrien Verschueren; Antonio Guglietta; Hans de Haard; Nicolas Leupin; Jan J G M Verschuuren
Journal:  Neurology       Date:  2019-05-22       Impact factor: 9.910

Review 2.  The Spectrum of Functional Rating Scales in Neurology Clinical Trials.

Authors:  Pushpa Narayanaswami
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

3.  The Impact of the Coronavirus Disease-2019 Pandemic on the Psychological Status and Quality of Life of Myasthenia Gravis Patients.

Authors:  Aleksandar Stojanov; Jelena Stojanov; Vuk Milosevic; Marina Malobabic; Goran Stanojevic; Milos Stevic; Gordana Djordjevic
Journal:  Ann Indian Acad Neurol       Date:  2020-05-08       Impact factor: 1.383

4.  Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE).

Authors:  Srikanth Muppidi; Richard J Nowak; Amanda C Guidon; Jeffrey T Guptill; Michael K Hehir; Katherine Ruzhansky; Leeann B Burton; David Post; Gary Cutter; Robin Conwit; Nicte I Mejia; Henry J Kaminski; James F Howard
Journal:  Muscle Nerve       Date:  2021-07-07       Impact factor: 3.852

Review 5.  Patient-Reported Outcomes Research in Neuro-Ophthalmology.

Authors:  Lindsey B De Lott; Joshua R Ehrlich
Journal:  J Neuroophthalmol       Date:  2021-06-01       Impact factor: 4.415

Review 6.  Understanding the burden of refractory myasthenia gravis.

Authors:  Christiane Schneider-Gold; Tim Hagenacker; Nico Melzer; Tobias Ruck
Journal:  Ther Adv Neurol Disord       Date:  2019-03-01       Impact factor: 6.570

7.  Prevalence and Associated Factors of Depressive Symptoms in Patients with Myasthenia Gravis: A Cross-Sectional Study of Two Tertiary Hospitals in Riyadh, Saudi Arabia.

Authors:  Mohammed H Alanazy
Journal:  Behav Neurol       Date:  2019-09-15       Impact factor: 3.342

8.  MuSK (Muscle Specific Kinase) Positive Myasthenia: Grave Prognosis or Undue Prejudice?

Authors:  Priyanka Samal; Vinay Goyal; Mamta B Singh; M V Padma Srivastava
Journal:  Ann Indian Acad Neurol       Date:  2020 Jan-Feb       Impact factor: 1.383

Review 9.  Application Prospect of Artificial Intelligence in Rehabilitation and Management of Myasthenia Gravis.

Authors:  Ying Zhang; Hongmei Yu; Rui Dong; Xuan Ji; Fujun Li
Journal:  Biomed Res Int       Date:  2021-03-04       Impact factor: 3.411

10.  Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.

Authors:  James F Howard; Richard J Nowak; Gil I Wolfe; Miriam L Freimer; Tuan H Vu; John L Hinton; Michael Benatar; Petra W Duda; James E MacDougall; Ramin Farzaneh-Far; Henry J Kaminski; Richard Barohn; Mazen Dimachkie; Mamatha Pasnoor; Constantine Farmakidis; Tina Liu; Samantha Colgan; Michael G Benatar; Tulio Bertorini; Rekha Pillai; Robert Henegar; Mark Bromberg; Summer Gibson; Teresa Janecki; Miriam Freimer; Bakri Elsheikh; Paige Matisak; Angela Genge; Amanda Guidon; William David; Ali A Habib; Veena Mathew; Tahseen Mozaffar; John L Hinton; William Hewitt; Deborah Barnett; Patricia Sullivan; Doreen Ho; James F Howard; Rebecca E Traub; Manisha Chopra; Henry J Kaminski; Radwa Aly; Elham Bayat; Mohammad Abu-Rub; Shaida Khan; Dale Lange; Shara Holzberg; Bhupendra Khatri; Emily Lindman; Tayo Olapo; Lisa M Sershon; Robert P Lisak; Evanthia Bernitsas; Kelly Jia; Rabia Malik; Tiffany D Lewis-Collins; Michael Nicolle; Richard J Nowak; Aditi Sharma; Bhaskar Roy; Joan Nye; Michael Pulley; Alan Berger; Yasmeen Shabbir; Amit Sachdev; Kimberly Patterson; Zaeem Siddiqi; Mark Sivak; Joan Bratton; George Small; Anem Kohli; Mary Fetter; Tuan Vu; Lucy Lam; Brittany Harvey; Gil I Wolfe; Nicholas Silvestri; Kara Patrick; Karen Zakalik; Petra W Duda; James MacDougall; Ramin Farzaneh-Far; Angela Pontius; Michelle Hoarty
Journal:  JAMA Neurol       Date:  2020-05-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.